Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.20

-0.8%

11:00 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bryce Elkins who wrote (18745)	4/7/1998 8:27:00 AM
From: Henry Niman	of 32384

Evista (Raloxifene) is slated for the new prevention trial, but neither LLY nor Evista was mentioned in the recent popular press coverage. Even though Raloxifene was mentioned, most viewers would not know that Raloxifene is Evista. I think that some posters have unrealistic expectations of the popular press. When the NY Times: www3.techstocks.com, Business Week On-Line: Message 3462385 and Financial Times did reviews on new treatments fo diabetes, LGND was mentioned. When the WSJ did a review of designer estrogens: home.att.net LGND was mentioned. Future reviews on breast cancer prevention drugs will mention LGND. Recent news is breaking news which generally do not include reviews.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next